Buy Wegovy Tablets Online with Free Consultation & Prescription

Other Related Names or Treatments

Wegovy Pills, Rybelsus, Semaglutide, Wegovy Injection, Ozempic

About Wegovy Tablets

Wegovy Tablets contain the active ingredient semaglutide, a human glucagon-like peptide-1 (GLP-1) analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist, selectively binding to and activating the GLP-1 receptor, a physiological regulator of appetite and calorie intake. By acting on areas of the brain involved in appetite regulation (in the hypothalamus and brainstem, and on areas involved in reward-based eating), semaglutide reduces hunger, increases feelings of fullness, lowers food cravings and reduces calorie intake, helping you lose weight and maintain weight loss.

Wegovy Tablets are taken once daily in the morning on an empty stomach. They are indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults aged 18 and over. The tablet is co-formulated with salcaprozate sodium, an absorption enhancer that protects semaglutide from stomach acid and facilitates its absorption across the stomach lining, which is why the strict fasting and water instructions must be followed for the medicine to work.

Wegovy Tablets are not a hormonal treatment and do not function as a contraceptive. They are a prescription-only medicine (Rx). As a needle-free, once-daily tablet that requires no refrigeration, Wegovy Tablets offer a convenient alternative to weekly injections for people who would prefer to avoid needles. Subject to your consultation, NowPatient offers Wegovy Tablets as a treatment for weight management following an online consultation with a prescriber.

Key facts of Wegovy Tablets

• For weight management (weight loss and weight maintenance) in adults with obesity, or in adults with overweight who also have at least one weight-related health problem
• The most common side effects are gastrointestinal (nausea, vomiting, diarrhea and constipation) and are mainly seen during dose escalation. Other common effects include headache, dizziness, tiredness and abdominal pain
• Wegovy Tablets must be taken on an empty stomach with no more than a small sip of water (up to 120 ml), and you must wait at least 30 minutes before eating, drinking or taking any other oral medicine
• Tablets should be swallowed whole; do not split, crush or chew them
• It can interact with other diabetes medicines such as insulin or sulfonylureas, increasing the risk of low blood sugar. Always tell your prescriber what else you take
• Wegovy Tablets are not a contraceptive and contain no hormones
• They should be used alongside a reduced-calorie diet and increased physical activity
• You should stop using Wegovy Tablets if your prescriber advises it is no longer needed, before a planned pregnancy, or if you experience serious side effects

How effective are Wegovy Tablets for weight loss?

Clinical studies have shown that Wegovy® tablets (oral semaglutide 25 mg) can help adults achieve significant and sustained weight loss when used alongside a reduced-calorie diet and increased physical activity.

The OASIS 4 clinical trial followed participants for 64 weeks, demonstrating that patients taking Wegovy Tablets lost substantially more weight than those receiving a placebo.

Key Results from the OASIS 4 Trial

What Do These Results Mean?

The study found that:

• Nearly 8 out of 10 people lost at least 5% of their starting body weight
• More than 6 out of 10 achieved a weight loss of 10% or more
• Half of participants lost at least 15% of their body weight
• Nearly 1 in 3 people achieved a weight loss of 20% or more

Weight loss began early in treatment and continued throughout the 64-week study. Importantly, these results were seen regardless of whether participants experienced gastrointestinal side effects, such as nausea or diarrhea.

Please note: Individual results may vary. Wegovy Tablets should only be used under the guidance of a healthcare professional and as part of a comprehensive weight management programme that includes healthy eating, physical activity, and lifestyle changes.

Who is Wegovy Tablets suitable for?

Wegovy Tablets are licensed for adults (18 years and over) for weight management as an adjunct to a reduced-calorie diet and increased physical activity, where there is:

• An initial Body Mass Index (BMI) of 30 kg/m² or greater (obesity), or
• An initial BMI of 27 kg/m² to less than 30 kg/m² (overweight) in the presence of at least one weight-related health problem, for example high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea

Efficacy has been demonstrated regardless of age, sex, race, ethnicity, baseline body weight, BMI and level of renal function, though results vary between individuals. Relatively greater weight loss has been seen in women and in people with a lower starting body weight.

Who is Wegovy Tablets not suitable for?

Wegovy Tablets are not suitable for everyone. Speak to the NowPatient prescribing clinician before using Wegovy Tablets if you:

• Are pregnant or planning to become pregnant. Wegovy should not be used in pregnancy and should be stopped at least 2 months before a planned pregnancy because of semaglutide’s long half-life
• Are breastfeeding or plan to breastfeed; Wegovy should not be used while breastfeeding
• Have had a serious allergic (hypersensitivity) reaction to semaglutide or any of the ingredients (salcaprozate sodium or magnesium stearate)
• Have had problems with your pancreas (pancreatitis), as semaglutide has not been studied in people with a history of pancreatitis and should be used with caution
• Have severe kidney problems. Wegovy is not recommended in severe renal impairment (eGFR below 30 ml/min/1.73 m²), including end-stage kidney disease
• Have severe liver problems. Wegovy is not recommended in severe hepatic impairment and should be used cautiously in mild to moderate impairment
• Have type 2 diabetes with diabetic retinopathy, which may need closer monitoring
• Have gastroparesis (delayed stomach emptying); Wegovy is not recommended if gastroparesis is severe
• Have severe heart failure (NYHA class IV), where there is no experience of use
• Are scheduled for surgery or a procedure involving general anesthesia or deep sedation, because of a risk of aspiration linked to delayed stomach emptying

Wegovy Tablets must not be used in combination with another GLP-1 receptor agonist, and must never be used as a substitute for insulin in people with diabetes. The safety and efficacy in children and adolescents under 18 have not been established.

How and where to get Wegovy Tablets?

You can buy Wegovy Tablets safely and securely from NowPatient. Start a consultation today for free; if you qualify for treatment, you only pay for the cost of the medication. Delivery is made to your home or office from our registered pharmacy.

Our service is certified, safe and effective. If you book a consultation with a prescribing clinician for the treatment of obesity or overweight, you can discuss whether Wegovy Tablets are a suitable option for you. At the end of the consultation, the clinician will decide whether a treatment plan is appropriate. If it is, they will issue a prescription, which can then be ordered, paid for and delivered directly to your chosen address by NowPatient.

Dosage and strength for Wegovy Tablets for weight loss

Wegovy Tablets are available in 1.5 mg, 4 mg, 9 mg and 25 mg strengths and are taken orally once daily. Wegovy must always be taken as only one tablet per day. Taking more than one tablet to achieve the effect of a higher dose should not be done.

The dose is increased gradually to reduce side effects:

• Starting dose: 1.5 mg once daily for one month
• Escalation: 4 mg, then 9 mg, then 25 mg, with a minimum of one month at each dose level
• Maintenance dose: 25 mg once daily, the maximum recommended single daily dose. If needed, the dose can be maintained at the previous level

How to take it:

• Take the tablet on an empty stomach after a fasting period of at least 8 hours (so, first thing in the morning)
• Swallow it whole with a small sip of water, up to half a glass (120 ml). Do not split, crush or chew the tablet, as this may affect how the medicine is absorbed
• Wait at least 30 minutes before eating, drinking or taking any other oral medicines. Waiting less than 30 minutes reduces absorption
• If you miss a dose, skip it and take your next dose the following day

If you have type 2 diabetes and take insulin or a sulfonylurea, your prescriber may reduce those doses when you start Wegovy to lower the risk of low blood sugar.

What happens if you use too many Wegovy Tablets?

Taking more than the prescribed amount will not speed up weight loss and can increase the risk of side effects. Overdose with semaglutide may be associated with gastrointestinal effects such as nausea, vomiting and diarrhea, which could lead to dehydration. There is no specific antidote; treatment is supportive. If you have taken too much and feel unwell, speak to your doctor, contact Poison Control on 1-800-222-1222, or reach out to one of our prescribing clinicians.

What are the side effects of Wegovy Tablets?

Side effects are grouped below by how often they occur. Most gastrointestinal effects appear during dose escalation, are mild to moderate, and improve over time.

Very common (may affect more than 1 in 10 people):

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal (stomach) pain
• Headache
• Tiredness (fatigue)
• Low blood sugar (hypoglycaemia) in people with type 2 diabetes

Common (may affect up to 1 in 10 people):

• Low blood sugar in people without type 2 diabetes
• Dizziness
• Altered taste (dysgeusia) and altered skin sensation (dysaesthesia)
• Indigestion (dyspepsia), heartburn / acid reflux (GORD), gastritis, burping, wind (flatulence) and bloating
• Increased heart rate
• Gallstones (cholelithiasis)
• Kidney stones (urolithiasis)
• Hair loss
• Increased blood levels of amylase, lipase and bilirubin
• Diabetic retinopathy in people with type 2 diabetes
• Hip fracture

Uncommon to rare:

• Acute pancreatitis (inflammation of the pancreas)
• Low blood pressure (hypotension) and orthostatic hypotension
• Allergic reactions, including anaphylactic reaction and angioedema (swelling)
• Delayed gastric emptying and, rarely, intestinal obstruction
• Non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye condition that can cause sudden loss of vision

Serious side effects. Seek medical advice promptly (your doctor or an urgent care center) if you notice:

• Severe, persistent stomach pain that will not go away (possible pancreatitis)
• Pain in the upper stomach, fever, or yellowing of the skin or eyes (possible gallbladder problems / gallstones)
• Signs of low blood sugar, especially if you also take other diabetes medicines
• Reduced urination or signs of dehydration from vomiting or diarrhea (possible kidney problems)
• Sudden loss of vision, including partial loss; stop Wegovy and seek urgent eye assessment

Call 911 if you have signs of a serious allergic reaction, such as: sudden swelling of the lips, mouth, throat or tongue; very fast breathing or struggling to breathe; a tight throat or difficulty swallowing; skin, tongue or lips turning blue, grey or pale; sudden confusion, drowsiness or dizziness; or someone faints and cannot be woken.

Managing mild side effects at home

Many of the common gastrointestinal effects ease as your body adjusts during dose escalation. The following may help:

• Eat smaller meals little and often through the day, rather than large meals
• Stick to plain, bland foods and avoid greasy, fatty or very rich meals
• Stay well hydrated by sipping water through the day, which also helps reduce the risk of dehydration
• Get adequate sleep (aim for at least 7 to 8 hours a night)
• Use over-the-counter pain relief for mild headaches or stomach discomfort, if suitable for you

If side effects do not improve, get worse, or include severe stomach pain or persistent vomiting, do not delay in seeking advice from your prescriber, primary care provider or an urgent care center.

Always report suspected side effects to the FDA MedWatch program at fda.gov/medwatch or by calling 1-800-FDA-1088.

Information about using Wegovy Tablets with other medications

Because semaglutide slows stomach emptying, it can affect the absorption of other oral medicines, and the presence of several tablets in the stomach at once can reduce how much semaglutide is absorbed, which is why you wait 30 minutes before any other oral medicine. Tell your prescribing clinician about everything you take. Key points from clinical data:

• Levothyroxine (thyroid medicine): total thyroxine exposure increased by about 33%. Monitoring of thyroid levels should be considered
• Warfarin and other coumarin anticoagulants: more frequent INR monitoring is recommended when starting Wegovy, as decreased INR has been reported with acenocoumarol
• Insulin and sulfonylureas: increased risk of low blood sugar; dose reductions may be needed
• Rosuvastatin: exposure increased by about 41%, but this is not considered clinically relevant
• No clinically relevant interaction was seen with digoxin, oral contraceptives (ethinylestradiol/levonorgestrel), metformin, furosemide or omeprazole. Oral contraceptive effectiveness is not affected

Why might Wegovy Tablets not work for weight loss?

The absorption of oral semaglutide is naturally variable, so following the dosing instructions exactly (empty stomach, only a small sip of water, and a 30-minute wait) is essential for the medicine to work. Adherence to the once-daily regimen and full dose titration schedule is recommended for the best effect. Weight loss occurs gradually: in clinical trials, meaningful weight loss was seen over a 64-week period and continued throughout. If your weight has not improved after reaching and maintaining the 25 mg dose, speak with your healthcare provider. Results vary between individuals.

How long do Wegovy Tablets take to work?

Wegovy Tablets begin acting on appetite within the first few days to weeks of daily use, as semaglutide reaches steady levels in the body after about 4 to 5 weeks of once-daily dosing. Many people notice reduced hunger early on, with visible weight loss typically starting around 4 to 8 weeks into treatment and continuing as the dose is increased toward the 25 mg maintenance level. Because the full effect builds over months, it is important to keep taking the tablet as prescribed and to combine it with a reduced-calorie diet and increased physical activity.

Can Wegovy Tablets be used long-term?

Yes. Wegovy Tablets can be used for as long as your clinician recommends. Once you reach your weight-management goals, your clinician may advise continuing treatment to help maintain your weight loss, as weight tends to be regained after stopping. Long-term use should always be monitored by a healthcare professional, who will review your progress, safety and dose at each follow-up.

How to store Wegovy Tablets

• Keep Wegovy Tablets out of the sight and reach of children
• Store the tablets in the original blister package to protect them from moisture and light. Keep each tablet in the blister until you are ready to take it
• No special temperature storage conditions are required
• Do not use this medicine after the expiry date (“EXP”) shown on the blister and carton. The expiry date refers to the last day of that month. The shelf life is 3 years
• Do not dispose of unused tablets in wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use; this helps protect the environment

Is there a herbal Wegovy Tablets?

No. There is no herbal version of Wegovy. If you have been offered such a product, it may be counterfeit or unsafe. Compounded or “herbal” semaglutide is not approved and may not be absorbed or effective without the specialised salcaprozate-sodium absorption technology used in genuine Wegovy Tablets. Only obtain Wegovy from a registered pharmacy following a prescription.

Cardiovascular benefits of Wegovy Tablets

Wegovy also shows significant cardiovascular benefits as a preventative for heart disease, helping to improve cardiovascular health even before weight loss occurs, by acting directly on blood vessels and the heart.

Heart Benefits of Wegovy include:

• Clinical trials have shown that a weekly dose of 2.4mg of Wegovy reduces the risk of strokes, heart attacks, and cardiovascular-related deaths by 20% in adult patients with established heart disease
• Clinical trials have also shown small reductions in blood pressure
• Wegovy helps to improve quality of life and physical function for those patients with heart failure and preserved ejection fraction
• Wegovy has been shown to reduce vascular inflammation and stabilize fatty plaques in arteries, which reduces the likelihood of clot formation
• Benefits to the heart are similar and independent of the weight lost by a patient

Should I avoid any particular food or drink when using Wegovy Tablets?

You must take Wegovy Tablets on an empty stomach with only a small sip of water (up to 120 ml), and wait at least 30 minutes before eating, drinking or taking other oral medicines. Taking the tablet with food or large volumes of water reduces how much medicine is absorbed. Beyond this, you can eat and drink normally, though you should follow a reduced-calorie diet as part of your weight-management plan. Eating smaller meals and avoiding very fatty foods can help reduce nausea, particularly during dose escalation.

What lifestyle changes can I make to help with weight loss?

Wegovy works best alongside healthy lifestyle changes:

• Follow a reduced-calorie diet as recommended by your healthcare provider
• Increase physical activity, aiming for at least 150 minutes of moderate exercise per week
• Eat more vegetables, fruit, whole grains and lean proteins
• Reduce sugary drinks, processed foods and high-fat foods
• Get adequate sleep (7–9 hours per night)
• Manage stress through relaxation techniques
• Stay hydrated by drinking plenty of water, which is important to reduce the risk of dehydration if you experience vomiting or diarrhea

Switching from Wegovy Injection to Wegovy Pills

You can discuss switching from Wegovy injection to Wegovy Tablets with your NowPatient clinician. The effect of switching cannot be predicted precisely, because oral semaglutide has more variable absorption than the injection. Generally, if you are using the once-weekly 2.4 mg Wegovy injection, you can be transitioned to Wegovy 25 mg tablets once daily. You can start the tablets one week after your last injection dose.

Wegovy Tablets vs Wegovy Injection

If you are weighing up the oral tablet against the once-weekly injection, both deliver the same active ingredient, semaglutide, but they differ in how they are taken, dosing frequency, storage and absorption. The table below sets out the key differences so you can see which format fits your lifestyle and treatment goals.

Your NowPatient clinician can help you decide which format suits you during your online consultation.

How do Wegovy Tablets compare to other weight loss treatments?

It can help to see how Wegovy Tablets measure up against other GLP-1 and incretin-based options. The table below summarises the average weight loss reported in the main Phase 3 clinical trials for each treatment. Because these figures come from separate trials with different durations, doses and patient groups, they are best used as a general guide rather than a direct head-to-head comparison. Your prescriber can help you choose the most suitable option for you.

While the higher-dose injectable treatments currently show greater average weight loss, Wegovy Tablets deliver clinically meaningful results in a needle-free, once-daily tablet, making them a strong choice for anyone who would prefer to avoid injections and refrigeration.

Alternatives to Wegovy Tablets

Alternatives for the treatment of obesity or overweight include:

Injectable treatments: Wegovy injection (semaglutide), Saxenda (liraglutide), Mounjaro (tirzepatide).

Oral treatments: Orlistat (Xenical / Alli), which works by blocking fat absorption; and Mysimba (naltrexone/bupropion). Alternatively, Eli Lilly’s Foundayo (orfoglipron) is due to be approved in late 2026 or early 2027.

Your NowPatient weight-loss clinician will help decide which option is most suitable for your needs and medical history.